Advertisement
Advertisement
U.S. markets close in 8 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Cybin Inc. (CYBN.NE)

NEO - NEO Real Time Price. Currency in CAD
Add to watchlist
0.6700-0.0100 (-1.47%)
As of 03:39PM EDT. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6800
Open0.6700
Bid0.6400 x 0
Ask0.6700 x 0
Day's Range0.6500 - 0.6900
52 Week Range0.5000 - 3.0000
Volume122,363
Avg. Volume149,615
Market Cap124.099M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3790
Earnings DateFeb 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for CYBN.NE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds

      TORONTO, September 27, 2022--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that, through its wholly-owned subsidiary Cybin IRL Limited, it has entered into an agreement with Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset") to acquire an exclusive license to an extensive targeted class of tryptamine-based molecules from Mindset (the "Agreement").

    • GlobeNewswire

      Mindset Pharma Provides Strategic Intellectual Property License to Cybin

      Licensing Subset of Mindset’s Family 1 Intellectual Property Underscores Strength of Mindset’s Portfolio and Business StrategyTORONTO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset”), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced an exclusive licensing agreement for Cybin Inc. (N

    • Market Exclusive

      Weekly Roundup on the Cannabis Sector & Psychedelic Sector

      Key Takeaways; Cannabis Sector High Tide’s third-quarter revenue rose 18% to C$95.4 million; in addition, the company closed a $19 million non-dilutive credit arrangement. Key Takeaways; Psychedelic Sector Cybin announced key research and development milestones, beating anticipated timeframe. Awakn reported strong Q2 earnings. The company also announced participation in a global investment conference. This week, […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared fir

    Advertisement
    Advertisement